|
|
||||||||||||||||
|
||||||||||||||||
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China. | ||||||||||||||||
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |